Next Health Reviews: The Membership Is Not the Bill

The one-sentence version

Next Health is the in-clinic end of this category: twenty centres selling NAD+ IV drips, peptide protocols, hormone optimisation and a deep lab menu, with memberships published openly from $99 a month to a $100,000-a-year application-only tier. It publishes far more pricing than most in-person clinics — and the membership is not the bill. An NAD+ infusion is $500 on top of it, and the same service costs a different amount depending on which of Next Health's own price lists you read. It grades B, 8 points out of 14, and the whole deduction is that gap. The grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

Founded in 2016 by Darshan Shah, MD and Kevin Peake, Next Health runs twenty locations — West Hollywood, Chicago, Nashville, Boston, Bellevue, Boulder, Dubai and more — with eight announced. Care is delivered in person: IV suites, cryotherapy, hyperbaric oxygen, blood draws and provider consults under one roof. Its own product pages refer to "Next Health, including its affiliates and franchisees", and it runs a franchise-inquiry funnel — the likeliest explanation for the pricing divergence below.

The buyer this suits wants to walk into a room and be treated today. The buyer it does not suit wants one figure that covers a year. See longevity clinics versus lab memberships and what longevity care costs.

What it actually costs

All figures verified on next-health.com on 26 July 2026. Note that the /pricing and /membership URLs both return 404; the live page is "become a member".

The memberships, published plainly. Medicine 4.0 at $99/month — quarterly biomarker testing, quarterly 1:1 consultations, and "access to provider-prescribed Peptides, Hormone Optimization, and Metabolic Programs." Optimize at $199, Premier at $299 ("our most popular membership"), Optimize 4.0 at $299 and Premier 4.0 at $399. And a Platinum tier at $100,000 a year, application-only, built around "quarterly Therapeutic Plasma Exchange (TPE) with Stem Cells/Exosomes."

Then the services, billed on top. NAD+ IV therapy is $500 for 300 mg and $1,000 for 750 mg — "a slow drip process… commonly takes between 2-3 hours" — plus a $175 add-on. Next Health recommends an "Optimal Aging Trifecta" of three infusions over seven days: $1,500 in a week at the lower tier, on top of a membership. Diagnostics are priced well — a Baseline Test of "over 50 biomarkers" at $349, a Galleri cancer test at $1,185, an Executive Physical at $14,500.

Two things are not priced at all: peptides and hormones. Next Health names sixteen peptides — BPC-157, DSIP, CJC-1295 with ipamorelin, tesamorelin, MOTS-c, Semax, PT-141, GHK-Cu among them — and prices none, stating that "access to a customized peptide protocol is exclusively available through a Next Health Medicine 4.0 Membership" and that "prescriptions are provided separately." The hormone page carries no figure at all. The two lines that make this a longevity clinic rather than a spa are the two with no published cost.

The two price lists

This is the finding that decides the grade. Next Health maintains a national store menu and separate per-location menus, and they do not agree — the store sells NAD+ IV therapy at $500 for 300 mg over two to three hours, while the New York City menu sells "NAD+ Therapy… ~30 Minute Service Time - $299." No page tells a buyer which list applies to them, and location pages advertise "up to 50% off membership rate" without stating the rate being discounted.

Clinical oversight, and one contradiction

Oversight is included and substantial: quarterly one-to-one consultations sit inside the $99 tier, peptides require a prescription, a medical director is named for the Los Angeles clinic, and Next Health states its physicians are regulated by the Medical Board of California. Membership terms, though, are published nowhere — no minimum term, no notice period, no auto-renewal language — and the refund policy covers products only, with "custom products (such as test kits and Peptides)" excluded.

Its peptide page also carries a straight self-contradiction, two lines apart: "Peptide Therapy does not require the assistance of a medical professional" directly above "our policy requires medical consultation and recommendation from a licensed provider for peptide therapy." On a page teaching readers to reconstitute lyophilised peptides and self-inject at home, that difference is not academic.

On pharmacy, nothing is classified: the strongest statement is "peptides compounded by trusted pharmacy partners" — no name, no 503A, no 503B. FDA's position is that compounded drugs are not FDA-approved, that it does not verify their safety, effectiveness or quality before marketing, and that 503A pharmacies are specifically not subject to current good manufacturing practice requirements¹.

The evidence behind what it sells

Next Health's NAD+ copy is the furthest past the evidence of anything on this page. It states that "NAD+ improves mitochondrial health and slows the aging process", promises "neuroprotection… for better mental clarity", lists "counteract hallmarks of aging" as a benefit, and argues that the intravenous route "ensures that 100% of this essential nutrient is directly delivered to your bloodstream" and is therefore "the most effective method."

The bioavailability argument is precisely where the literature is emptiest. The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found outcomes "heterogeneous and often null or endpoint-specific", clinical effectiveness "inconclusive", and reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for anti-aging or wellness indications at all². A $500 two-hour infusion is sold on the route with no outcomes trial behind it. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time³. See NAD+ for longevity and do NAD+ peptides actually work.

On peptides, the page promises "specific, measurable effects… from body composition and recovery to cognition" within "1–2 cycles." Two named compounds are growth-hormone secretagogues, and the trial record is unkind: the landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events⁴. To its credit, Next Health states these therapies "are not FDA-approved to diagnose, treat, cure, or prevent any disease." And on biological age, its executive-physical page says providers "may help you reverse your epigenetic age" — an outcome no completed trial supports. See peptides for longevity and epigenetic clock comparison.

Where it's weak, and who should skip it

Skip it if you are buying the NAD+ drip for energy or clarity: it is the most expensive way to buy the molecule on this board, by the route with no outcomes trial. Skip it if you need a total — peptides and hormones, the reason a longevity buyer walks in, carry no published price at either tier.

If you proceed, price it at your specific clinic rather than the national store, and ask for peptide and hormone costs before joining the $99 tier that gates them.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Next Health takes the longevity line in full — NAD+, sixteen named peptides, hormone optimisation and a 50-marker diagnostic line is squarely what this board ranks — plus two for provider consultations inside the membership and two for a care model that includes human time rather than upselling it. It takes zero on price transparency, and it is worth being exact about why: not for hiding prices, since it publishes more than most in-person clinics, but because the membership is not the cost, the two therapeutic lines are unpriced, two of its own price lists disagree by up to 40%, and no membership term is published anywhere. Zero on pharmacy. Eight of fourteen. A B.

Reconcile the location menus with the national one, put a number on peptides and hormones, and drop the claim that an IV drip slows aging — and this becomes one of the better-documented in-person programs in the category, because the underlying operation already is. The full field is at our provider rankings, the scoring is in how we grade, and two comparable programs are in our Marek Health review and Fountain Life review.